Status and phase
Conditions
Treatments
About
This is a Phase 1, First-in-human, double-blinded, placebo-controlled study which aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the immunogenicity of KN069 in Chinese male participants with Obesity or Overweight.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
36 participants in 5 patient groups
Loading...
Central trial contact
Yanrong Dong, Master
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal